Hexarelin, also called examorelin, is a synthetic hexapeptide growth-hormone secretagogue studied in humans mainly for hormone testing and endocrine responses. Human trials show it can stimulate growth hormone and other pituitary-adrenal hormones, but this does not prove benefits for fat loss, anti-aging, or muscle gain. Chia does not offer hexarelin.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
Hexarelin is also called examorelin. It is a synthetic hexapeptide, meaning it is a lab-made peptide made of 6 amino acids, and it belongs to a group called growth-hormone secretagogues.
A growth-hormone secretagogue is a compound studied for its ability to trigger growth hormone release from the pituitary gland. Human clinical research has tested hexarelin in people with hypothalamic-pituitary abnormalities and in people with growth hormone deficiency, mainly by measuring growth hormone responses after exposure 1 12.
Names, class, and basic definition
- Common names: hexarelin and examorelin.
- Class: synthetic growth-hormone secretagogue peptide.
- Structure: synthetic hexapeptide.
- Main research use in the supplied human records: endocrine-response testing, including growth hormone, ACTH, cortisol, and prolactin measurements 5 8.
- What is not shown in these records: proven long-term fat loss, anti-aging, athletic-performance, or muscle-gain outcomes.
How hexarelin differs from growth hormone itself
Hexarelin is not growth hormone. It is studied as a signal that can prompt growth hormone release, while growth hormone itself is the hormone released by the pituitary gland; human trials in this evidence set measured the body’s hormone response to hexarelin rather than treating hexarelin as replacement growth hormone 1 12.
That difference matters. A short-term rise in growth hormone or related hormones does not prove better body composition, longer life, better athletic performance, or safer long-term use.
Mechanism of action
Hexarelin is studied as a growth-hormone secretagogue, which means it can stimulate growth hormone release in human endocrine-testing studies. In this evidence set, researchers measured hormone outputs such as growth hormone, ACTH, cortisol, and prolactin after hexarelin exposure 7 8.
Mechanistically, growth-hormone secretagogues are commonly discussed through the growth hormone secretagogue receptor, also called the ghrelin receptor. The supplied human records directly support the endocrine-response point: hexarelin was shown in human research to stimulate growth hormone and to affect pituitary-adrenal hormones, including ACTH and cortisol 5 8.
Growth-hormone secretagogue activity
In patients with different hypothalamic-pituitary abnormalities, researchers studied the growth hormone response to hexarelin 1. In patients with growth hormone deficiency, another human clinical study also evaluated growth hormone secretion after hexarelin 12.
Food intake may matter for the hormone signal. A human study specifically examined the role of food intake in modulating hexarelin-induced growth hormone release in normal human subjects 11.
Pituitary-adrenal and prolactin effects seen in human studies
Hexarelin is not limited to growth hormone signaling in the human records. A dose-response study reported hexarelin-induced growth hormone, cortisol, and prolactin release 7.
Another human randomized controlled trial concluded that the growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin 5. A separate clinical trial examined chronic hexarelin administration and its effects on the pituitary-adrenal axis and prolactin 3.
Evidence
Evidence grade: A. The assigned grade is based on the presence of 2 or more human randomized controlled trials, not on proven real-world benefit.
A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
The human literature in this evidence set is real, but it is narrow. It includes randomized controlled trials and clinical trials that measured endocrine responses, including growth hormone, cortisol, ACTH, and prolactin, rather than long-term outcomes like fat loss, muscle gain, metabolic disease risk, or longevity 5 7 8.
What outcomes were studied
The strongest theme across the supplied human records is hormone testing. Studies assessed growth hormone response in hypothalamic-pituitary abnormalities, growth hormone deficiency, normal subjects, and endocrine testing contexts 1 11 12.
Other studies looked at pituitary-adrenal hormones. For example, randomized and clinical studies examined ACTH, cortisol, prolactin, arginine vasopressin pathways, and possible desensitization with repeated administration 3 5 8 9.
What has not been proven for patients
The supplied studies do not prove that hexarelin causes fat loss, builds muscle, improves athletic performance, slows aging, or improves long-term metabolic health. Short-term hormone changes are not the same as patient-centered outcomes.
Some human research used special clinical settings, such as alcohol-induced pseudo-Cushing’s syndrome and coronary artery disease during bypass surgery 2 4. Those settings should not be generalized to consumer performance, bodybuilding, or longevity claims.
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 1998 | Clinical trial | The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities | The Journal of clinical endocrinology and metabolism | PMID 9814463 |
| 2000 | Randomised controlled trial | Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome | Journal of internal medicine | PMID 10886488 |
| 1999 | Clinical trial | The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin | Clinical endocrinology | PMID 10341859 |
| 2002 | Clinical trial | Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery | European journal of pharmacology | PMID 12144941 |
| 1999 | Randomised controlled trial | The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin | The Journal of clinical endocrinology and metabolism | PMID 10404825 |
| 1998 | Clinical trial | Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children | Minerva endocrinologica | PMID 10361807 |
| 2002 | Randomised controlled trial | Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion i | European journal of endocrinology | PMID 11888836 |
| 1998 | Clinical trial | Does desensitization to hexarelin occur? | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society | PMID 10990150 |
| 2003 | Clinical trial | Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans | Journal of endocrinological investigation | PMID 14594107 |
| 2000 | Clinical trial | Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme | PMID 10824712 |
| 1995 | Clinical trial | The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency | The Journal of clinical endocrinology and metabolism | PMID 7673411 |
| 1997 | Randomised controlled trial | Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in | Neuroendocrinology | PMID 9430449 |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.
Reported dosing ranges
Reported dosing in this section means what published human studies described, not what any reader should use. The retrieved records available here include study schedules and testing contexts, but most citation records do not provide full dose amounts in the supplied source text.
| Source | Population or setting | Route or schedule reported in the retrieved record | What was measured | What this does not mean |
|---|---|---|---|---|
| Maccario et al., 2002 8 | Humans in a randomized endocrine study | Two or three daily subcutaneous injections were studied | 24-hour growth hormone, prolactin, ACTH, and cortisol secretion | Not a personal dosing plan |
| Massoud et al., 1996 7 | Human dose-response study | Dose-response design reported; dose amounts are not provided in the retrieved citation text | Growth hormone, cortisol, and prolactin release | Does not prove long-term benefit or safety |
| Rahim et al., 1999 3 | Human clinical trial of chronic administration | Chronic administration was studied; schedule details are not provided in the retrieved citation text | Pituitary-adrenal axis and prolactin | Does not establish consumer-use safety |
| Rahim and Shalet, 1998 9 | Human clinical trial | Repeated-administration question studied; exact dose schedule is not provided in the retrieved citation text | Whether desensitization to hexarelin occurs | Does not provide dosing advice |
| De Marinis et al., 2000 11 | Normal human subjects | Food-intake modulation study; exact dose schedule is not provided in the retrieved citation text | Hexarelin-induced growth hormone release | Does not show how a person should time or take it |
Routes and schedules reported in human trials
The clearest schedule detail in the retrieved records comes from Maccario et al., who studied two or three daily subcutaneous injections of hexarelin and measured 24-hour hormone secretion in humans 8. Other records describe acute, chronic, dose-response, or testing contexts but do not provide enough dosing detail in the supplied citation text to build a dosing range 3 7 9.
Legal status
Our regulatory log holds no confirmed federal action for Hexarelin. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.
Safety
Safety questions with hexarelin start with the same biology that makes it interesting: it can affect hormone systems. Human studies in this evidence set measured growth hormone, prolactin, ACTH, and cortisol responses, which means a clinician would want to think beyond growth hormone alone 3 5 8.
The supplied human records do not establish long-term consumer safety. Many records focus on endocrine testing or special clinical contexts, such as hypothalamic-pituitary abnormalities, growth hormone deficiency, alcohol-induced pseudo-Cushing’s syndrome, or bypass-surgery settings 1 2 4 12.
Hormone-related effects to discuss with a clinician
- Growth hormone and IGF-1 questions, because hexarelin has been studied for growth hormone release in humans 1 12.
- ACTH and cortisol questions, because human studies measured pituitary-adrenal responses and cortisol release 5 7 8.
- Prolactin questions, because prolactin release and chronic prolactin-related effects were studied in humans 3 7 8.
- Desensitization questions, because human clinical research specifically asked whether desensitization to hexarelin occurs 9.
- Food-timing and testing questions, because food intake was studied as a factor that may modulate hexarelin-induced growth hormone release 11.
Why long-term consumer safety is not established by short endocrine studies
A trial that measures hormones over a short study window can answer one type of question: what changed in that protocol. It cannot, by itself, prove long-term safety for goals such as body recomposition, healthy aging, or performance.
People with pituitary, adrenal, endocrine, metabolic, cardiovascular, cancer-related, pregnancy, breastfeeding, or pediatric concerns should be especially careful with hormone-active substances. The supplied studies include endocrine and cardiovascular testing settings, but they do not provide broad safety data for unsupervised use 1 4 12.
Supply quality risks
A separate safety issue is supply quality. Products sold online as “research use only” are not made for human care, and the main risks include sterility, identity, strength, and impurity problems; this is why we steer patients toward licensed clinical evaluation and licensed pharmacy channels for treatments that are part of their care.
Interactions
Interaction data for hexarelin are limited in the supplied human records. No dedicated drug-drug interaction study is included in this evidence set, so lack of documented interactions should not be read as proof of safety.
Other hormone-active medicines or peptides
Because hexarelin has been studied for effects on growth hormone, ACTH, cortisol, and prolactin, combining it with other hormone-active medicines or peptides raises monitoring questions that should be handled by a clinician 5 7 8.
Somatostatin-14 and cortistatin-14 have been studied for their effects on endocrine responses to hexarelin in humans 10. That is interaction-relevant biology, but it is not the same as a full consumer drug-interaction guide.
Glucose, cortisol, prolactin, GH, and IGF-1 monitoring questions
- Ask how growth hormone and IGF-1 would be interpreted if a hormone-active peptide is being discussed, because hexarelin studies focus on growth hormone response 1 12.
- Ask whether ACTH and cortisol matter in your case, because hexarelin has been studied for hypothalamo-pituitary-adrenal axis effects 5.
- Ask whether prolactin should be monitored, because prolactin responses were measured in human studies 3 7 8.
- Ask whether food intake affects testing or interpretation, because food intake was studied as a modulator of hexarelin-induced growth hormone release 11.
How to obtain it legally
Chia does not offer hexarelin. If you are considering any hormone-active peptide, the safer process starts with a licensed clinician reviewing your health history, medications, goals, risks, and labs where appropriate.
A clinician evaluation is not a formality. For a growth-hormone secretagogue, the discussion should include pituitary and adrenal history, metabolic concerns, cancer history, pregnancy or breastfeeding, pediatric use, cardiovascular history, and whether the evidence actually matches your goal.
A licensed pharmacy is different from a research-chemical vendor. A pharmacy dispensing for patient care works within a clinician-directed treatment process; a “research use only” seller is not a medical evaluation, not a prescription, and not a patient-care pharmacy.
If your goal is healthy aging, body composition, or GH-axis support, it may be more useful to compare options with better-defined clinical pathways. Chia offers sermorelin as injections, nasal spray, and tablets, with plans currently starting at $179/mo; treatment is 100% online, reviewed by a licensed US provider, compounded by state-licensed US 503A pharmacies, and shipped to the patient’s door when prescribed. A prescription requires a medical evaluation and is not guaranteed; compounded medications are not FDA-approved.
For education on related peptides, see our guides to ipamorelin, CJC-1295, and how to buy sermorelin online safely. These are not interchangeable with hexarelin, but they help frame common GH-axis questions.
If your goal is healthy aging, body composition, or GH-axis support
Start with the goal, not the compound. Someone asking about body composition may need nutrition, resistance training, sleep, metabolic labs, or weight-management care; someone asking about fatigue or recovery may need a different workup.
If you are comparing peptide categories, our articles on peptides for bodybuilding and muscle-building peptides explain why hormone changes, performance claims, and safety evidence should be kept separate.
How does hexarelin compare with related peptides?
Hexarelin sits in the broader GH-axis peptide conversation, but it should not be treated as the same thing as sermorelin, ipamorelin, or CJC-1295. The main distinction is that the supplied hexarelin evidence focuses on endocrine responses and testing contexts 1 5 8.
| Peptide | Basic category | Main patient-facing question | Chia connection |
|---|---|---|---|
| Hexarelin / examorelin | Synthetic growth-hormone secretagogue | Human studies show hormone responses, but not proven fat-loss, muscle-gain, longevity, or performance outcomes 5 7 8 | Chia does not offer hexarelin |
| Sermorelin | GH-axis peptide discussed for growth-hormone signaling | Often compared with other GH-axis peptides, but not interchangeable with hexarelin | Chia offers sermorelin as injection, nasal spray, and tablets |
| Ipamorelin | Growth-hormone secretagogue peptide | Often discussed in GH-axis and body-composition forums; evidence and safety should be reviewed separately | Education-only article: ipamorelin |
| CJC-1295 | Growth-hormone-releasing hormone analog category | Often discussed with GH-axis peptides; mechanism differs from hexarelin | Education-only article: CJC-1295 |
Hexarelin vs sermorelin
Hexarelin is a growth-hormone secretagogue studied in human endocrine-response settings 1 8. Sermorelin is a different GH-axis peptide and should not be treated as a substitute for hexarelin; if sermorelin is being considered, it needs its own clinical review.
Hexarelin vs ipamorelin and CJC-1295
Ipamorelin and CJC-1295 are often discussed near hexarelin because all three sit in the GH-axis conversation. But mechanism, evidence, safety, and access questions differ, so comparing them requires compound-by-compound review rather than assuming a shared effect.
Hexarelin is studied as a growth-hormone secretagogue, meaning it can stimulate growth hormone release in human endocrine studies. Human research also measured cortisol, ACTH, and prolactin responses. These hormone changes do not prove fat loss, muscle gain, anti-aging, or athletic-performance benefits.
Yes. Hexarelin is also called examorelin. It is a synthetic hexapeptide in the growth-hormone secretagogue category.
The supplied human studies do not prove that hexarelin burns fat or causes weight loss. They mainly measured hormone responses such as growth hormone, cortisol, ACTH, and prolactin.
The evidence set used for this article does not show proven muscle-building outcomes in patients. A hormone response is not the same as a demonstrated increase in muscle mass or strength.
The human studies in this evidence set measured endocrine responses during research protocols. They do not establish a patient timeline for body-composition, performance, or longevity goals.
People with pituitary, adrenal, endocrine, metabolic, cardiovascular, cancer-related, pregnancy, breastfeeding, or pediatric concerns should discuss hormone-active substances with a licensed clinician before considering them.
The retrieved human records include study schedules such as two or three daily subcutaneous injections in one endocrine study, but the available citation text does not provide enough detail to create a personal dosing range. Study schedules are not dosing instructions.
No. Chia does not offer hexarelin. Chia does offer clinician-reviewed care for certain listed treatments, including sermorelin, but sermorelin is a different peptide and is not interchangeable with hexarelin.
References
- 1.Maghnie M, Spica-Russotto V, Cappa M, et al. The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities. The Journal of clinical endocrinology and metabolism. 1998.
- 2.Coiro V, Volpi R, Capretti L, et al. Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome. Journal of internal medicine. 2000.
- 3.Rahim A, O'Neill PA, Shalet SM. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clinical endocrinology. 1999.
- 4.Broglio F, Guarracino F, Benso A, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. European journal of pharmacology. 2002.
- 5.Korbonits M, Kaltsas G, Perry LA, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. The Journal of clinical endocrinology and metabolism. 1999.
- 6.Guzzaloni G, Grugni G, Morabito F. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children. Minerva endocrinologica. 1998.
- 7.Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. The Journal of clinical endocrinology and metabolism. 1996.
- 8.Maccario M, Veldhuis JD, Broglio F, et al. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. European journal of endocrinology. 2002.
- 9.Rahim A, Shalet SM. Does desensitization to hexarelin occur?. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1998.
- 10.Benso A, Gottero C, Prodam F, et al. Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans. Journal of endocrinological investigation. 2003.
- 11.De Marinis L, Mancini A, Valle D, et al. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2000.
- 12.Loche S, Cambiaso P, Merola B, et al. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. The Journal of clinical endocrinology and metabolism. 1995.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
